Logo image of IART

INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IART - US4579852082 - Common Stock

12.01 USD
-0.4 (-3.22%)
Last: 1/20/2026, 8:00:02 PM
12.01 USD
0 (0%)
After Hours: 1/20/2026, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, IART scores 4 out of 10 in our fundamental rating. IART was compared to 186 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • IART had positive earnings in the past year.
  • IART had a positive operating cash flow in the past year.
  • IART had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years IART had a positive operating cash flow.
IART Yearly Net Income VS EBIT VS OCF VS FCFIART Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

  • The Return On Assets of IART (-13.58%) is comparable to the rest of the industry.
  • IART's Return On Equity of -47.74% is in line compared to the rest of the industry. IART outperforms 51.61% of its industry peers.
  • With a decent Return On Invested Capital value of 4.27%, IART is doing good in the industry, outperforming 74.73% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.84%.
Industry RankSector Rank
ROA -13.58%
ROE -47.74%
ROIC 4.27%
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
IART Yearly ROA, ROE, ROICIART Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8 10

1.3 Margins

  • Looking at the Operating Margin, with a value of 10.22%, IART is in the better half of the industry, outperforming 79.03% of the companies in the same industry.
  • In the last couple of years the Operating Margin of IART has declined.
  • IART has a Gross Margin (57.21%) which is in line with its industry peers.
  • IART's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.22%
PM (TTM) N/A
GM 57.21%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
IART Yearly Profit, Operating, Gross MarginsIART Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
  • IART has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IART has been reduced compared to 5 years ago.
  • IART has a worse debt/assets ratio than last year.
IART Yearly Shares OutstandingIART Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IART Yearly Total Debt VS Total AssetsIART Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • Based on the Altman-Z score of 1.24, we must say that IART is in the distress zone and has some risk of bankruptcy.
  • IART's Altman-Z score of 1.24 is in line compared to the rest of the industry. IART outperforms 52.69% of its industry peers.
  • A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.73, IART is doing worse than 80.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Altman-Z 1.24
ROIC/WACC0.55
WACC7.81%
IART Yearly LT Debt VS Equity VS FCFIART Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that IART has no problem at all paying its short term obligations.
  • IART has a Current ratio (3.14) which is in line with its industry peers.
  • IART has a Quick Ratio of 1.80. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
  • IART has a Quick ratio of 1.80. This is comparable to the rest of the industry: IART outperforms 48.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 1.8
IART Yearly Current Assets VS Current LiabilitesIART Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

4

3. Growth

3.1 Past

  • IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
  • IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
  • The Revenue has been growing slightly by 4.99% in the past year.
  • IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.20% yearly.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%

3.2 Future

  • IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.68% yearly.
  • IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.39% yearly.
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IART Yearly Revenue VS EstimatesIART Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
IART Yearly EPS VS EstimatesIART Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.07, the valuation of IART can be described as very cheap.
  • 98.39% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
  • IART is valuated cheaply when we compare the Price/Earnings ratio to 26.94, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 5.01 indicates a rather cheap valuation of IART.
  • IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 99.46% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, IART is valued rather cheaply.
Industry RankSector Rank
PE 5.07
Fwd PE 5.01
IART Price Earnings VS Forward Price EarningsIART Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 95.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.73
IART Per share dataIART EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.22%
EPS Next 3Y1.53%

0

5. Dividend

5.1 Amount

  • IART does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (1/20/2026, 8:00:02 PM)

After market: 12.01 0 (0%)

12.01

-0.4 (-3.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30
Earnings (Next)02-23
Inst Owners95.82%
Inst Owner Change0.62%
Ins Owners3.07%
Ins Owner Change0.13%
Market Cap935.46M
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (31.64%)
Short Float %11.02%
Short Ratio8.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)0%
PT rev (3m)-5.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-5.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.35%
Valuation
Industry RankSector Rank
PE 5.07
Fwd PE 5.01
P/S 0.57
P/FCF N/A
P/OCF 10.47
P/B 0.9
P/tB N/A
EV/EBITDA 7.73
EPS(TTM)2.37
EY19.73%
EPS(NY)2.4
Fwd EY19.97%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY9.55%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
Industry RankSector Rank
ROA -13.58%
ROE -47.74%
ROCE 5.11%
ROIC 4.27%
ROICexc 4.65%
ROICexgc 11.32%
OM 10.22%
PM (TTM) N/A
GM 57.21%
FCFM N/A
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Debt/EBITDA 5.62
Cap/Depr 68.73%
Cap/Sales 6.32%
Interest Coverage 250
Cash Conversion 28.01%
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 1.8
Altman-Z 1.24
F-Score5
WACC7.81%
ROIC/WACC0.55
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.61%
EBIT Next 3Y9.61%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%

INTEGRA LIFESCIENCES HOLDING / IART FAQ

Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?

ChartMill assigns a fundamental rating of 4 / 10 to IART.


What is the valuation status for IART stock?

ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.


What is the profitability of IART stock?

INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.


What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?

The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.